Payment overview · 2025
General Payments
$145.59
9 reported records · 6 companies
Healthcare provider profile · identity verified
Jayne B Leonard, MD
Allopathic & Osteopathic Physicians|Family Medicine · JEFFERSON, NC · NPI 1457391401
Verified facts
What the public records show
CMS Open Payments records show Jayne B Leonard, MD received $145.59 in general payments during 2025 across 9 reported records.
Amgen Inc. accounted for 32.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.73 | 32.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.00 | 22.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.98 | 13.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.50 | 12.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.92 | 10.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.46 | 9.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $145.59 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.73 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.73 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.00 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 580 | 135 |
| Omeprazole | Omeprazole | 355 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 322 | 89 |
| Hydrochlorothiazide | Hydrochlorothiazide | 282 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 232 | 61 |
| Lisinopril | Lisinopril | 231 | 60 |
| Tramadol Hcl | Tramadol Hcl | 226 | 48 |
| Trazodone Hcl | Trazodone Hcl | 219 | 46 |
| Metformin Hcl | Metformin Hcl | 203 | 58 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 185 | 28 |
| Losartan Potassium | Losartan Potassium | 164 | 45 |
| Alendronate Sodium | Alendronate Sodium | 159 | 42 |
| Potassium Chloride | Potassium Chloride | 153 | 36 |
| Clonazepam | Clonazepam | 152 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 150 | 40 |
| Gabapentin | Gabapentin | 139 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 134 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 131 | 30 |
| Alprazolam | Alprazolam | 122 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 111 | 32 |
| Montelukast Sodium | Montelukast Sodium | 110 | 24 |
| Famotidine | Famotidine | 108 | 27 |
| Sertraline Hcl | Sertraline Hcl | 100 | 25 |
| Eliquis | Apixaban | 98 | 19 |
| Furosemide | Furosemide | 96 | 31 |
| Prednisone | Prednisone | 96 | 56 |
| Oxycodone Hcl | Oxycodone Hcl | 95 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 90 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 72 |
| Simvastatin | Simvastatin | 89 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 16 |
| Donepezil Hcl | Donepezil Hcl | 81 | 24 |
| Allopurinol | Allopurinol | 78 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 26 |
| Lorazepam | Lorazepam | 77 | 17 |
| Spironolactone | Spironolactone | 72 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 16 |
| Azithromycin | Azithromycin | 68 | 40 |
| Benazepril Hcl | Benazepril Hcl | 65 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 18 |
| Pregabalin | Pregabalin | 60 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 56 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 23 |
| Meloxicam | Meloxicam | 55 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 17 |
| Aripiprazole | Aripiprazole | 52 | 13 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 50 | 50 |
| Fentanyl | Fentanyl | 48 | suppressed |
| Bupropion Xl | Bupropion Hcl | 46 | 11 |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 33 |
| Doxazosin Mesylate | Doxazosin Mesylate | 43 | 11 |
| Meclizine Hcl | Meclizine Hcl | 43 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 32 |
| Divalproex Sodium | Divalproex Sodium | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 37 | 33 |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 30 |
| Celecoxib | Celecoxib | 35 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 34 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Verapamil Er | Verapamil Hcl | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | 13 |
| Fluconazole | Fluconazole | 29 | 20 |
| Levofloxacin | Levofloxacin | 29 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 12 |
| Atenolol | Atenolol | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 17 |
| Promethazine Hcl | Promethazine Hcl | 26 | 11 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 19 |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 20 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Carvedilol | Carvedilol | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Armodafinil | Armodafinil | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $145.59 · 9 records | Amgen Inc. | Cologuard Collection Kit, GEMTESA, OTEZLA, Ozempic, REPATHA, Symbravo, YUPELRI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error